Medical Aesthetics: A Rising Tide Lifts All Ships In A Booming Market With Room For Growth
Major players in medical aesthetics are investing in the overall growth of the market in the hope that a rising tide will lift all ships. Research shows that while millions have tried facial injectables and other non-invasive treatments, many more need one last push into the dermatologist's office.
You may also be interested in...
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
Boehringer expects Jardiance’s new chronic kidney disease indication to keep its sales growing by double-digit percentages over the coming years, aided by the drug’s ability to reduce hospitalizations.
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.